M&T Bank Corp Sells 5,924 Shares of Edwards Lifesciences Corporation (NYSE:EW)

M&T Bank Corp lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 14.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,974 shares of the medical research company's stock after selling 5,924 shares during the period. M&T Bank Corp's holdings in Edwards Lifesciences were worth $2,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of EW. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Vega Investment Solutions bought a new stake in Edwards Lifesciences in the fourth quarter worth $27,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth $29,000. Global X Japan Co. Ltd. increased its position in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after purchasing an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC increased its position in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after purchasing an additional 205 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In related news, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the sale, the vice president directly owned 33,496 shares of the company's stock, valued at $2,514,879.68. This represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,348 shares of company stock valued at $2,977,683 over the last quarter. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Citigroup restated a "buy" rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Finally, Evercore ISI boosted their price target on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the stock an "in-line" rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of "Hold" and an average price target of $80.40.

Edwards Lifesciences Trading Down 0.9%

Shares of EW traded down $0.73 during trading hours on Friday, reaching $78.07. 3,780,176 shares of the company traded hands, compared to its average volume of 5,256,833. The firm has a market cap of $45.79 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.96 and a beta of 1.11. Edwards Lifesciences Corporation has a 12-month low of $58.93 and a 12-month high of $92.88. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock's fifty day moving average price is $76.30 and its 200 day moving average price is $73.38.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business's revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.66 earnings per share. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.